Literature DB >> 23913756

Population-specific frequencies for LRRK2 susceptibility variants in the Genetic Epidemiology of Parkinson's Disease (GEO-PD) Consortium.

Michael G Heckman1, Alexandra I Soto-Ortolaza, Jan O Aasly, Nadine Abahuni, Grazia Annesi, Justin A Bacon, Soraya Bardien, Maria Bozi, Alexis Brice, Laura Brighina, Jonathan Carr, Marie-Christine Chartier-Harlin, Efthimios Dardiotis, Dennis W Dickson, Nancy N Diehl, Alexis Elbaz, Carlo Ferrarese, Brian Fiske, J Mark Gibson, Rachel Gibson, Georgios M Hadjigeorgiou, Nobutaka Hattori, John P A Ioannidis, Magdalena Boczarska-Jedynak, Barbara Jasinska-Myga, Beom S Jeon, Yun Joong Kim, Christine Klein, Rejko Kruger, Elli Kyratzi, Suzanne Lesage, Chin-Hsien Lin, Timothy Lynch, Demetrius M Maraganore, George D Mellick, Eugénie Mutez, Christer Nilsson, Grzegorz Opala, Sung Sup Park, Simona Petrucci, Andreas Puschmann, Aldo Quattrone, Manu Sharma, Peter A Silburn, Young Ho Sohn, Leonidas Stefanis, Vera Tadic, Jessie Theuns, Hiroyuki Tomiyama, Ryan J Uitti, Enza Maria Valente, Christine Van Broeckhoven, Simone van de Loo, Demetrios K Vassilatis, Carles Vilariño-Güell, Linda R White, Karin Wirdefeldt, Zbigniew K Wszolek, Ruey-Meei Wu, Faycal Hentati, Matthew J Farrer, Owen A Ross.   

Abstract

BACKGROUND: Variants within the leucine-rich repeat kinase 2 gene are recognized as the most frequent genetic cause of Parkinson's disease. Leucine-rich repeat kinase 2 variation related to disease susceptibility displays many features that reflect the nature of complex, late-onset sporadic disorders like Parkinson's disease.
METHODS: The Genetic Epidemiology of Parkinson's Disease Consortium recently performed the largest genetic association study for variants in the leucine-rich repeat kinase 2 gene across 23 different sites in 15 countries.
RESULTS: Herein, we detail the allele frequencies for the novel risk factors (p.A419V and p.M1646T) and the protective haplotype (p.N551K-R1398H-K1423K) nominated in the original publication. Simple population allele frequencies not only can provide insight into the clinical relevance of specific variants but also can help genetically define patient groups.
CONCLUSIONS: Establishing individual patient-based genomic susceptibility profiles that incorporate both risk factors and protective factors will determine future diagnostic and treatment strategies.
© 2013 Movement Disorder Society.

Entities:  

Keywords:  LRRK2; Parkinson's disease; association study; genetics

Mesh:

Substances:

Year:  2013        PMID: 23913756      PMCID: PMC4108155          DOI: 10.1002/mds.25600

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  15 in total

1.  alpha-Synuclein locus triplication causes Parkinson's disease.

Authors:  A B Singleton; M Farrer; J Johnson; A Singleton; S Hague; J Kachergus; M Hulihan; T Peuralinna; A Dutra; R Nussbaum; S Lincoln; A Crawley; M Hanson; D Maraganore; C Adler; M R Cookson; M Muenter; M Baptista; D Miller; J Blancato; J Hardy; K Gwinn-Hardy
Journal:  Science       Date:  2003-10-31       Impact factor: 47.728

2.  Multiple LRRK2 variants modulate risk of Parkinson disease: a Chinese multicenter study.

Authors:  Eng-King Tan; Rong Peng; Yik-Ying Teo; Louis C Tan; Dario Angeles; Patrick Ho; Meng-Ling Chen; Chin-Hsien Lin; Xue-Ye Mao; Xue-Li Chang; Kumar M Prakash; Jian-Jun Liu; Wing-Lok Au; Wei-Dong Le; Joseph Jankovic; Jean-Marc Burgunder; Yi Zhao; Ruey-Meei Wu
Journal:  Hum Mutat       Date:  2010-05       Impact factor: 4.878

3.  Independent and joint effects of the MAPT and SNCA genes in Parkinson disease.

Authors:  Alexis Elbaz; Owen A Ross; John P A Ioannidis; Alexandra I Soto-Ortolaza; Frédéric Moisan; Jan Aasly; Grazia Annesi; Maria Bozi; Laura Brighina; Marie-Christine Chartier-Harlin; Alain Destée; Carlo Ferrarese; Alessandro Ferraris; J Mark Gibson; Suzana Gispert; Georgios M Hadjigeorgiou; Barbara Jasinska-Myga; Christine Klein; Rejko Krüger; Jean-Charles Lambert; Katja Lohmann; Simone van de Loo; Marie-Anne Loriot; Timothy Lynch; George D Mellick; Eugénie Mutez; Christer Nilsson; Grzegorz Opala; Andreas Puschmann; Aldo Quattrone; Manu Sharma; Peter A Silburn; Leonidas Stefanis; Ryan J Uitti; Enza Maria Valente; Carles Vilariño-Güell; Karin Wirdefeldt; Zbigniew K Wszolek; Georgia Xiromerisiou; Demetrius M Maraganore; Matthew J Farrer
Journal:  Ann Neurol       Date:  2011-03-09       Impact factor: 10.422

4.  Genomic investigation of alpha-synuclein multiplication and parkinsonism.

Authors:  Owen A Ross; Adam T Braithwaite; Lisa M Skipper; Jennifer Kachergus; Mary M Hulihan; Frank A Middleton; Kenya Nishioka; Julia Fuchs; Thomas Gasser; Demetrius M Maraganore; Charles H Adler; Lydie Larvor; Marie-Christine Chartier-Harlin; Christer Nilsson; J William Langston; Katrina Gwinn; Nobutaka Hattori; Matthew J Farrer
Journal:  Ann Neurol       Date:  2008-06       Impact factor: 10.422

5.  Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease.

Authors:  Wataru Satake; Yuko Nakabayashi; Ikuko Mizuta; Yushi Hirota; Chiyomi Ito; Michiaki Kubo; Takahisa Kawaguchi; Tatsuhiko Tsunoda; Masahiko Watanabe; Atsushi Takeda; Hiroyuki Tomiyama; Kenji Nakashima; Kazuko Hasegawa; Fumiya Obata; Takeo Yoshikawa; Hideshi Kawakami; Saburo Sakoda; Mitsutoshi Yamamoto; Nobutaka Hattori; Miho Murata; Yusuke Nakamura; Tatsushi Toda
Journal:  Nat Genet       Date:  2009-11-15       Impact factor: 38.330

6.  Clinical and biomarker changes in dominantly inherited Alzheimer's disease.

Authors:  Randall J Bateman; Chengjie Xiong; Tammie L S Benzinger; Anne M Fagan; Alison Goate; Nick C Fox; Daniel S Marcus; Nigel J Cairns; Xianyun Xie; Tyler M Blazey; David M Holtzman; Anna Santacruz; Virginia Buckles; Angela Oliver; Krista Moulder; Paul S Aisen; Bernardino Ghetti; William E Klunk; Eric McDade; Ralph N Martins; Colin L Masters; Richard Mayeux; John M Ringman; Martin N Rossor; Peter R Schofield; Reisa A Sperling; Stephen Salloway; John C Morris
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

7.  Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice.

Authors:  Youren Tong; Hiroo Yamaguchi; Emilie Giaime; Scott Boyle; Raphael Kopan; Raymond J Kelleher; Jie Shen
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-10       Impact factor: 11.205

8.  Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies.

Authors:  Michael A Nalls; Vincent Plagnol; Dena G Hernandez; Manu Sharma; Una-Marie Sheerin; Mohamad Saad; J Simón-Sánchez; Claudia Schulte; Suzanne Lesage; Sigurlaug Sveinbjörnsdóttir; Kári Stefánsson; Maria Martinez; John Hardy; Peter Heutink; Alexis Brice; Thomas Gasser; Andrew B Singleton; Nicholas W Wood
Journal:  Lancet       Date:  2011-02-01       Impact factor: 79.321

9.  LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors.

Authors:  Kelly M Hinkle; Mei Yue; Bahareh Behrouz; Justus C Dächsel; Sarah J Lincoln; Erin E Bowles; Joel E Beevers; Brittany Dugger; Beate Winner; Iryna Prots; Caroline B Kent; Kenya Nishioka; Wen-Lang Lin; Dennis W Dickson; Christopher J Janus; Matthew J Farrer; Heather L Melrose
Journal:  Mol Neurodegener       Date:  2012-05-30       Impact factor: 14.195

10.  Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database.

Authors:  Christina M Lill; Johannes T Roehr; Matthew B McQueen; Fotini K Kavvoura; Sachin Bagade; Brit-Maren M Schjeide; Leif M Schjeide; Esther Meissner; Ute Zauft; Nicole C Allen; Tian Liu; Marcel Schilling; Kari J Anderson; Gary Beecham; Daniela Berg; Joanna M Biernacka; Alexis Brice; Anita L DeStefano; Chuong B Do; Nicholas Eriksson; Stewart A Factor; Matthew J Farrer; Tatiana Foroud; Thomas Gasser; Taye Hamza; John A Hardy; Peter Heutink; Erin M Hill-Burns; Christine Klein; Jeanne C Latourelle; Demetrius M Maraganore; Eden R Martin; Maria Martinez; Richard H Myers; Michael A Nalls; Nathan Pankratz; Haydeh Payami; Wataru Satake; William K Scott; Manu Sharma; Andrew B Singleton; Kari Stefansson; Tatsushi Toda; Joyce Y Tung; Jeffery Vance; Nick W Wood; Cyrus P Zabetian; Peter Young; Rudolph E Tanzi; Muin J Khoury; Frauke Zipp; Hans Lehrach; John P A Ioannidis; Lars Bertram
Journal:  PLoS Genet       Date:  2012-03-15       Impact factor: 5.917

View more
  15 in total

Review 1.  Understanding the GTPase Activity of LRRK2: Regulation, Function, and Neurotoxicity.

Authors:  An Phu Tran Nguyen; Darren J Moore
Journal:  Adv Neurobiol       Date:  2017

Review 2.  Mechanisms of LRRK2-dependent neurodegeneration: role of enzymatic activity and protein aggregation.

Authors:  Md Shariful Islam; Darren J Moore
Journal:  Biochem Soc Trans       Date:  2017-02-08       Impact factor: 5.407

3.  Protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variants.

Authors:  Michael G Heckman; Alexis Elbaz; Alexandra I Soto-Ortolaza; Daniel J Serie; Jan O Aasly; Grazia Annesi; Georg Auburger; Justin A Bacon; Magdalena Boczarska-Jedynak; Maria Bozi; Laura Brighina; Marie-Christine Chartier-Harlin; Efthimios Dardiotis; Alain Destée; Carlo Ferrarese; Alessandro Ferraris; Brian Fiske; Suzana Gispert; Georgios M Hadjigeorgiou; Nobutaka Hattori; John P A Ioannidis; Barbara Jasinska-Myga; Beom S Jeon; Yun Joong Kim; Christine Klein; Rejko Kruger; Elli Kyratzi; Chin-Hsien Lin; Katja Lohmann; Marie-Anne Loriot; Timothy Lynch; George D Mellick; Eugénie Mutez; Grzegorz Opala; Sung Sup Park; Simona Petrucci; Aldo Quattrone; Manu Sharma; Peter A Silburn; Young Ho Sohn; Leonidas Stefanis; Vera Tadic; Hiroyuki Tomiyama; Ryan J Uitti; Enza Maria Valente; Demetrios K Vassilatis; Carles Vilariño-Güell; Linda R White; Karin Wirdefeldt; Zbigniew K Wszolek; Ruey-Meei Wu; Georgia Xiromerisiou; Demetrius M Maraganore; Matthew J Farrer; Owen A Ross
Journal:  Neurobiol Aging       Date:  2013-08-17       Impact factor: 4.673

4.  Understanding the role of genetic variability in LRRK2 in Indian population.

Authors:  Asha Kishore; Ashwin Ashok Kumar Sreelatha; Marc Sturm; Felix von-Zweydorf; Lasse Pihlstrøm; Francesco Raimondi; Rob Russell; Peter Lichtner; Moinak Banerjee; Syam Krishnan; Roopa Rajan; Divya Kalikavil Puthenveedu; Sun Ju Chung; Peter Bauer; Olaf Riess; Christian Johannes Gloeckner; Rejko Kruger; Thomas Gasser; Manu Sharma
Journal:  Mov Disord       Date:  2018-11-28       Impact factor: 10.338

5.  Identification of LRRK2 missense variants in the accelerating medicines partnership Parkinson's disease cohort.

Authors:  Nicole Bryant; Nicole Malpeli; Julia Ziaee; Cornelis Blauwendraat; Zhiyong Liu; Andrew B West
Journal:  Hum Mol Genet       Date:  2021-04-30       Impact factor: 6.150

6.  LRRK2 p.M1646T is associated with glucocerebrosidase activity and with Parkinson's disease.

Authors:  Yuri L Sosero; Eric Yu; Lynne Krohn; Uladzislau Rudakou; Kheireddin Mufti; Jennifer A Ruskey; Farnaz Asayesh; Sandra B Laurent; Dan Spiegelman; Stanley Fahn; Cheryl Waters; S Pablo Sardi; Sara Bandres-Ciga; Roy N Alcalay; Ziv Gan-Or; Konstantin Senkevich
Journal:  Neurobiol Aging       Date:  2021-02-28       Impact factor: 5.133

7.  Studying the Genetics of Complex Disease With Ancestry-Specific Human Phenotype Networks: The Case of Type 2 Diabetes in East Asian Populations.

Authors:  Jingya Qiu; Jason H Moore; Christian Darabos
Journal:  Genet Epidemiol       Date:  2016-04-07       Impact factor: 2.135

8.  A LRRK2 GTP Binding Inhibitor, 68, Reduces LPS-Induced Signaling Events and TNF-α Release in Human Lymphoblasts.

Authors:  Tianxia Li; Bo Ning; Lingbo Kong; Bingling Dai; Xiaofei He; Joseph M Thomas; Akira Sawa; Christopher A Ross; Wanli W Smith
Journal:  Cells       Date:  2021-02-23       Impact factor: 6.600

9.  Understanding LRRK2 kinase activity in preclinical models and human subjects through quantitative analysis of LRRK2 and pT73 Rab10.

Authors:  Xiang Wang; Elvira Negrou; Michael T Maloney; Vitaliy V Bondar; Shan V Andrews; Manuel Montalban; Ceyda Llapashtica; Romeo Maciuca; Hoang Nguyen; Hilda Solanoy; Annie Arguello; Laralynne Przybyla; Nathan J Moerke; Sarah Huntwork-Rodriguez; Anastasia G Henry
Journal:  Sci Rep       Date:  2021-06-18       Impact factor: 4.379

10.  Protective LRRK2 R1398H Variant Enhances GTPase and Wnt Signaling Activity.

Authors:  Jonathon Nixon-Abell; Daniel C Berwick; Simone Grannó; Victoria A Spain; Craig Blackstone; Kirsten Harvey
Journal:  Front Mol Neurosci       Date:  2016-03-08       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.